Retatrutide, originally developed by Eli Lilly, has found a loyal fan base—even though clinical trials of the drug still ...

Women with polycystic ovary syndrome are increasingly turning to blockbuster weight-loss drugs from Eli Lilly and Novo ...

Step aside, semaglutide—retatrutide is showing the most impressive weight loss results of any obesity drug to date.

The weight-loss drug market is booming, with biotech firms racing to secure their place in a lucrative sector currently ...

Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...

The Mumbai-based drugmaker, in a regulatory filing, said it has the rights to distribute and promote Yurpeak, the second anti ...

FDA-approved weight loss medications include injections (Wegovy®, Zepbound®, etc.) and pills, like Qsymia® and Xenical®. Most ...

Telemedicine prescriptions of semaglutide and tirzepatide, combined with a virtual behavioral program, yielded weight loss ...

Okava Pharmaceuticals, a San Francisco based company, plans to introduce on Tuesday a new GLP-1 clinical weight loss study ...

GLP-1 medicines cause malnutrition in 22% of patients. Multivitamins are often inadequate. Patients need dietitian support ...

Research is important to us for many reasons. Sometimes, for example, research results in a new treatment (e.g., Alexander Fleming and penicillin), a new idea (e.g., Einstein's theory of relativity), ...

The WHO released new guidance on GLP-1 medications for adults with obesity, recommending their long-term, continuous use when ...